DNA — Ginkgo Bioworks Holdings Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Annual cashflow statement for Ginkgo Bioworks Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-127	-1,837	-2,106	-893	-547
Depreciation
Deferred Taxes
Non-Cash Items	3.54	1,615	1,863	498	255
Unusual Items
Purchased R&D
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-26.5	-61.5	-37	29.8	-89.7
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities	-136	-254	-252	-296	-320
Capital Expenditures	-57.8	-56.5	-52.3	-40.8	-62.5
Purchase of Fixed Assets
Other Investing Cash Flow Items	-9.3	-16.7	-15.1	-39.9	0.305
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-67.1	-73.3	-67.4	-80.7	-62.2
Financing Cash Flow Items	—	50.5	-2.97	-2.01	-0.926
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	90.3	1,534	95.3	-3.22	-1.74
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-113	1,207	-223	-380	-384